Empowering mAb Discovery: Advantages of our humanized antibody (RenMab™) mouse model
Highest range of human Vh and Vk diversity
RenMab™ mice carry the full human variable region repertoire, allowing for the in vivo discovery of fully human antibodies with high affinity, low immunogenicity, and favorable developability.
In vivo discovery allows for the natural pairing of human heavy and light chains, which minimizes the need for excessive rounds of late-stage antibody engineering and validation that is necessary when using other in vitro discovery methods.
RenMab™ mice harbor the full human variable domain in situ
Biocytogen’s humanized RenMab™ mouse was generated using chromosome engineering. This proprietary, Mb-scale editing technology enabled the efficient replacement of the entire murine immunoglobulin heavy chain and kappa light chain variable domains (including distal Vk) with the corresponding human immunoglobulin variable domains in situ.
Native/intact VDJ gene regulation
The use of our chromosome engineering technology means that the entire human immunoglobulin locus, including the noncoding regions surrounding the VDJ loci, remains intact in the RenMab™ model.
Maturation and selection of human antibodies in vivo
To ensure robust immune cell responses and proper B cell development, the murine constant region in the RenMab™ family remains intact. The constant domain is then easily swapped with the human constant domain at later stages.
Maximum diversity
The germline gene usage of naïve B cells closely mimics human gene usage. Thus, RenMab™ mice generate a highly diverse B cell repertoire for the maximum recovery of successful antibody hits with high affinity.
Low Immunogenicity
When murine antibodies are humanized in vitro prior to drug development, they have a higher probability of generating an anti-drug immune response (ADA). Producing fully human antibodies in our RenMab™ model ensures that your antibody candidates will be of higher quality and have a higher success rate during clinical development.
Gene editing RenMab™ mice
For highly homologous and challenging targets (such as GPCRs), our team has knocked out key target genes in RenMab™/RenLite® humanized antibody models, to allow for more robust hit generation.
Learn more about the RenMice HiTS (Hyperimmune Target Specific) Platform and view the recent progress of the HiTS Library. Antibody licensing and partnership opportunities are available.
Visit Renmab.com
Biocytogen’s RenMab™ and RenLite® humanized antibody mouse models are powerful tools for generating fully human antibodies.
